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Knowledge  on the  role  of Helicobacter  pylori  (HP)  infection  is continually  evolving, and  treatment  is
becoming  more  challenging  due to increasing  bacterial  resistance.  Since  the  management  of  HP  infection
is  changing,  an  update  of  the national  Italian  guidelines  delivered  in 2007  was  needed.  In the III  Working
Group  Consensus  Report  2015,  a  panel  of  17 experts  from  several  Italian  regions  reviewed  current  evi-
dence on  different  topics  relating  to HP  infection.  Four  working  groups  examined  the following  topics:  (1)
“open  questions”  on  HP  diagnosis  and treatment  (focusing  on  dyspepsia,  gastro-oesophageal  reﬂux  dis-
ease,  non-steroidal  anti-inﬂammatory  drugs  or aspirin  use and  extra-gastric  diseases);  (2)  non-invasivetaly
anagement
and invasive  diagnostic  tests;  (3) treatment  of  HP  infection;  (4)  role  of  HP  in  the  prevention  of  gastric
cancer.  Statements  and  recommendations  were  discussed  and  a consensus  reached  in  a ﬁnal  plenary
session  held  in  February  2015  in Bologna.  Recommendations  are  based  on the  best current  evidence  to
help  physicians  manage  HP  infection  in Italy.  The  guidelines  have  been  endorsed  by  the  Italian  Society
of  Gastroenterology  and  the  Italian  Society  of  Digestive  Endoscopy.
© 2015  Editrice  Gastroenterologica  Italiana  S.r.l.  Published  by Elsevier  Ltd.  All  rights  reserved.. IntroductionOur knowledge on the role of Helicobacter pylori (HP) in different
linical conditions has improved over the last decade, whereas the
reatment of infection has become more challenging. According to
∗ Corresponding author at: Department of Medical and Surgical Sciences, Univer-
ity  of Bologna, Policlinico Sant’Orsola-Malpighi, Via Massarenti n. 9, 40138 Bologna,
taly. Tel.: +39 051 6364117; fax: +39 051 6364117.
E-mail address: roccomaurizio.zagari@unibo.it (R.M. Zagari).
ttp://dx.doi.org/10.1016/j.dld.2015.06.010
590-8658/© 2015 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. Allthe European guidelines the management of HP may  differ among
European countries (i.e. indications for a test- and- treat strat-
egy, the regimen to choose for ﬁrst-line treatment) in parallel
with different prevalence rates of infection and levels of antimi-
crobial resistance, in particular to clarithromycin [1]. Attempts to
standardize HP management within countries have led to the pub-
lication of several national guidelines, and Gastroenterologists and
referring physicians have been shown to comply with these guide-
lines [2]. This is the third time a group of Italian experts convenes
to review and discuss the relevant evidence concerning the clin-
ical management of HP infection in Italy [3,4]. As HP testing and
 rights reserved.
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Table 1
Grades of recommendation and levels of evidence [1].
Grade of rec-
ommendation
Level of
evidence
Type of study
A 1 1a Systematic review of RCTs
of good methodological
quality and with
homogeneity
1b Individual RCT with narrow
95% conﬁdence interval
1c  Individual RCT with risk of
bias
B 2 2a Systematic review of
cohort studies
2b Individual cohort studies
(including low quality RCT,
<80% follow-up)
2c Non-controlled cohort
studies or ecological
studies
3  3a Systematic review of
case-control studies
3b Individual case-control
study
C 4 Case series or poor quality
cohort or case-control
studies
D  5 Expert opinion without
explicit critical appraisal or
based on physiology, bench
research or “ﬁrst
principles”
RCT, randomized controlled trial.04 R.M. Zagari et al. / Digestive an
reatment should be managed in close cooperation between spe-
ialists and general practitioners, it is particularly important that
ata on diagnostic tools and therapeutic approaches be applied
ppropriately in clinical practice in speciﬁc national settings.
This consensus project aimed to summarize current evidence
n the management of HP infection and update the Italian guide-
ines produced in the II Working Group Report 2006 [4]. At the III
orking Group Consensus Report 2015, 17 experts from different
talian regions, chosen for their expertise and research contribution
n HP and/or guideline methodology, convened at an ofﬁcial meet-
ng by the coordinator (MC) of the two previous working group
eetings [3,4]. Italian experts focused on updating indications,
iagnosis and treatment of HP and its relationship with gastric
ancer.
. Methodology and consensus meeting structure
The guidelines are endorsed by the Italian Society of Gastroen-
erology (SIGE) and the Italian Society of Digestive Endoscopy
SIED), which were not however promoters of the Consensus. Rep-
esentatives from both SIGE (MR  and FDM) and SIED (RMZ and CC)
articipated to the Consensus process. A panel of Italian gastroen-
erologists and pathologists met  in April 2014 in Ferrara, where
urrent European guidelines – Maastricht IV/Florence – [1] were
eviewed at the introductory plenary session. The panel further
greed on the “Maastricht methodology” to be applied [1], on a set
f key questions to be addressed and on preliminary statements to
uide literature research. The panel worked in subgroups (working
roups) to perform a systematic literature search, review state-
ents on the basis of best available evidence and report graded
tatements and recommendations. Four working groups examined
he following topics:
1) “Open questions” for HP diagnosis and treatment, focusing
on dyspepsia, gastro-oesophageal reﬂux disease (GORD), use
of non-steroidal anti-inﬂammatory drugs (NSAIDs) or aspirin
(acetylsalicylic acid – ASA) and extra-gastric diseases
2) Non-invasive and invasive diagnostic tests
3) Treatment of HP
4) Role of HP treatment in the prevention of gastric cancer
For each topic, individual key questions were addressed. The
uality level of evidence and the strength of recommendation
ere graded according to the same system used in the Maastricht
V/Florence report (Table 1) [1]. After discussion, the working group
roduced statements with the level of available evidence and the
trength of the recommendation. Researchers prioritized data from
ystematic reviews and meta-analyses of randomized controlled
rials (RCTs) when available, or individual RCTs with narrow 95%
onﬁdence intervals (CI). The clinical applicability of statements
nd recommendations and their implementations in primary care
ere also taken into account.
Statements and recommendations with supporting evidence
ere edited and discussed at a one-day ﬁnal plenary session in
ebruary 2015 in Bologna. After a thorough discussion, all partici-
ants were asked to vote on their agreement with evidence-based
tatements, and consensus was deﬁned when at least 70% of partic-
pants agreed with the statement. Recommendations are based on
he best current evidence to aid physicians manage HP infection in
taly. Previous strong indications for HP eradication, such as peptic
lcer and gastric mucosa associated lymphoid tissue (MALT) [4],
ave been reconﬁrmed.3. Statements
3.1. Open questions for diagnosis and treatment
3.1.1. HP and dyspepsia
Several well-designed studies support the use of the HP test-
and-treat for the initial management of uninvestigated dyspepsia in
young patients without alarm signs or symptoms (i.e. unintentional
weight loss, iron-deﬁciency anaemia, gastrointestinal bleeding,
dysphagia) [5]. European guidelines recommend this strategy in
countries where HP prevalence is higher than 20% [1]. In Italy, as
well as in other Southern European countries, such as Greece and
Spain, HP prevalence in adults is around 50% [6,7]. Thus, a test-and-
treat strategy is still recommended in Italy. The speciﬁc cut-off age
for referring patients with uninvestigated dyspepsia without alarm
symptoms to endoscopy is controversial; it depends on the local
age-speciﬁc incidence of gastric cancer [1]. The Italian cancer reg-
istry shows that the incidence of gastric cancer increases in subjects
over 50 years of age [8]. In addition, a recent Italian survey reported
a very low prevalence of gastric cancer (0.3%) in approximately one
thousand patients referred for upper endoscopy [9]. Based on these
data, a cut-off age of 50 years in Italy should be appropriate. There-
fore, all dyspeptic patients older than 50 years or with alarm signs or
symptoms should be referred for upper endoscopy [10]. When the
test-and-treat strategy is applied, an accurate diagnosis is manda-
tory using a non-invasive test, either the 13C-urea breath test (UBT)
or the monoclonal stool antigen test (SAT) [1].
Many dyspeptic patients have no major lesions at endoscopy [6]
and some of these are HP-infected (functional dyspepsia). A recent
meta-analysis demonstrated that 1 out of 13 HP-infected patients
with functional dyspepsia beneﬁt from eradication [11]. Therefore,
HP eradication is recommended in this setting.
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tatement: HP test-and-treat strategy is appropriate for the ini-
ial management of uninvestigated dyspepsia as HP prevalence
n adults in Italy is over 20%. This approach is applicable to
atients younger than 50 years without alarm symptoms.
vidence level: 1a; Grade of recommendation: A
.1.2. HP and gastro-oesophageal reﬂux disease
An increasing body of evidence supports the suggestion of
 protective role of HP against GORD by reducing gastric acid
ecretion. Several meta-analyses showed a statistically signiﬁcant
ower prevalence of HP in GORD patients [12], including those
ith Barrett’s oesophagus [13] or oesophageal adenocarcinoma
14], than in controls. In addition, a recent RCT in Asia reported an
ncreased prevalence of reﬂux oesophagitis after HP eradication
15]. This data are in contrast with a previous meta-analysis
howing no association between HP eradication and development
f new cases of GORD in dyspeptic patients [16]. However, the
hort follow-up after eradication may  account for the discrepancy
etween studies. HP eradication does not seem to exacerbate the
isease in patients with GORD, thus HP infection in GORD patients
ay  be eradicated [17]. Further supporting HP eradication in
ORD patients is the need for long-term proton pump inhibitor
PPI) therapy that seems to be associated with an increased risk
f developing gastric precancerous conditions, such as corpus
trophic gastritis [18,19].
tatement: Increasing evidence supports a negative association
etween HP infection and GORD, including its complications
oesophagitis, Barrett’s oesophagus and oesophageal adenocar-
inoma). However, HP eradication does not worsen pre-existing
ORD nor does it affect proton pump inhibitor treatment efﬁ-
acy.
vidence level: 1b; Grade of recommendation: A
.1.3. HP and NSAIDs/ASA
HP infection is associated with an increased risk of uncompli-
ated and complicated gastro-duodenal ulcers in NSAID and ASA
sers [1]. There are no relevant additional studies addressing the
ole of HP in NSAIDs or ASA users, and data concerning the role
f HP in patients taking low dose of ASA are still scarce. In agree-
ent with international guidelines [1,20], HP should be searched
nd eradicated in all NSAID or ASA users with a history of peptic
lcer disease. In addition, as the combination of NSAID/ASA therapy
ith other risks factors for gastrointestinal (GI) bleeding increases
he risk of upper gastrointestinal events [20] an HP test-and-treat
ay  also be considered in NSAID/ASA users with multiple risk
actors for upper gastrointestinal bleeding: combined NSAIDs and
SA, or concomitant anticoagulant therapy (i.e., un-fractionated or
ow-molecular-weight heparin and warfarin), clopidogrel or corti-
osteroids.
HP eradication seems to be more beneﬁcial before starting long-
erm NSAIDs/ASA treatment [1]. However, after HP eradication
hese patients still require continuous PPI treatment [1,20].
There are no recent studies on subjects who chronically use
orticosteroids (i.e., patients with inﬂammatory bowel disease or
heumatologic diseases). The problem whether this subgroup of
atients could beneﬁt from HP eradication remains open. In recent
ears, new anticoagulant drugs with a high risk of GI bleeding
ave been introduced for the prevention and treatment of myocar-
ial infarction, stroke, and atrial ﬁbrillation [21,22]. The absence of
andomized controlled trials does not allow to provide recommen-
ations for these patients.r Disease 47 (2015) 903–912 905
Statements:
HP eradication reduces the risk of complicated and uncompli-
cated gastro-duodenal ulcers associated with either NSAID or
low-dose ASA use. HP eradication is more beneﬁcial before start-
ing NSAID treatment.
Evidence level: 1b; Grade of recommendation: A
HP eradication is mandatory in chronic NSAID/ASA users with
a peptic ulcer history.
Evidence level: 2b; Grade of recommendation: B
Eradication of HP may  be considered in chronic NSAID/ASA users
with multiple risk factors (both NSAID and ASA use or concomi-
tant anticoagulant, clopidogrel or corticosteroid use) for upper
GI bleeding.
Evidence level: 5; Grade of recommendation: D
3.1.4. HP and extra-gastric diseases
The association of HP with otherwise unexplained iron-
deﬁciency anaemia, diagnosed after endoscopic exclusion of the
most common bleeding (i.e. cancer, peptic ulcer) and non-bleeding
(i.e. celiac disease, previous gastric surgery) GI diseases [23,24],
has been well ascertained and demonstrated in a recent meta-
analysis (Odds Ratio [OR]: 2.2; 95%CI, 1.52–3.24) [25]. Two  further
meta-analyses showed that HP eradication combined with oral
iron supplementation is superior to iron supplementation alone for
moderate to severe unexplained iron-deﬁciency anaemia [26,27].
However, it should be noted that only corpus mucosa involve-
ment and development of corpus gastritis links HP infection to
iron-deﬁciency anaemia [28].
Regarding idiopathic thrombocytopenic purpura (ITP), a meta-
analysis [29] and two  systematic reviews [30,31] demonstrated
that HP eradication induced a signiﬁcant increase in platelet count.
For example, Arnold et al. showed an increase in platelet count in
51% of eradicated patients vs. 8.8% of non-eradicated patients with
ITP [30].
A recent systematic review of 17 studies, including 2454 sub-
jects, addressed the association between HP and cobalamin levels
in patients with unexplained vitamin B12 deﬁciency. HP-positive
subjects showed signiﬁcantly lower cobalamin levels than HP-
negative ones (mean difference: −0.74, 95% CI: −1.15 to −0.34)
[32]. Moreover, a sub-group analysis on the effect of eradica-
tion on cobalamin levels showed signiﬁcantly lower levels before
eradication [32].
Recent data showed an association between CagA-positive HP
strains and ischaemic heart disease [33,34]. In addition, it has been
suggested that HP might be playing a pathogenic role in rosacea
[35]. However, there is not enough evidence to suggest HP testing
in these clinical settings.
Statements:
There is substantial evidence in favour of an associa-
tion between HP infection and unexplained iron-deﬁciency
anaemia, ITP and vitamin B12 deﬁciency. Therefore, in these
conditions HP should be sought and treated.
Evidence level: 1a; Grade of recommendation: A (Unexplained iron-
deﬁciency anaemia)
Evidence level: 1b; Grade of recommendation: A (ITP)
Evidence level: 1b; Grade of recommendation: A (Vitamin B12 deﬁ-
ciency)
3.2. Diagnosis3.2.1. Non-invasive tests
Several meta-analyses conﬁrmed that 13C-UBT is the best test
for the non-invasive HP diagnosis with a 96% sensitivity and a 93%
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peciﬁcity [36]. A meta-analysis showed that the laboratory ELISA
onoclonal SAT has a similar high accuracy for both the initial and
ost-treatment diagnosis [37]. The rapid in-ofﬁce monoclonal SAT,
ased on an immunochromatographic technique, seems to be less
ccurate [38].
However, the recent use of PPIs (within 2 weeks) or antimi-
robials (within 4 weeks) may  lead to a decrease in the gastric
acterial load causing false-negative results [39–41]. Bleeding can
lso reduce the sensitivity of both UBT and SAT [39,40]. Data from
 systematic review suggests repeating diagnostic tests in patients
ith bleeding ulcer after at least 4 weeks in case of a negative
esult [42]. In patients with precancerous conditions or gastric
ancer, as well as in patients with partial gastrectomy, diagnostic
ests may  have lower accuracy [42].
tatements:
oth 13C-UBT and monoclonal SAT have shown high diagnostic
ccuracy in both the pre- and post-HP treatment setting.
vidence level: 1a; Grade of recommendation: A
he following conditions reduce the sensitivity of 13C-urea UBT
nd SAT: use of antibiotics during the previous month, inability
o stop proton pump inhibitors for at least 2 weeks, bleeding
lcer, atrophic gastritis and gastric malignancies.
vidence level: 1b; Grade of recommendation: B
Serology is commonly used for the diagnosis of HP infection.
hen 13C-UBT or SAT cannot be used (i.e. current anti-secretory or
ntibiotic use) or are unavailable, a validated IgG serology test with
ntibodies against whole HP bacterial body can be used. However,
lthough anti-HP IgG titre is not affected by conditions reducing HP
acterial load, it cannot discriminate between active or past infec-
ion. Anti-HP IgG titre usually remains elevated for long periods
fter clearance or eradication [1].
Determination of anti-CagA antibodies alone is not appropriate
o diagnose HP infection. In Western countries, the seroprevalence
f anti-CagA antibodies is less than 50% in infected individuals
nd anti-CagA antibodies are detectable for years after eradication
43].
tatement: Positive IgG serology with antibodies against whole
P bacteria only indicates past, but not necessarily ongoing,
nfection.
vidence level: 1b; Grade of recommendation: A
.2.2. Invasive endoscopy-based tests
The working group did not deem it useful to draw up new state-
ents on histology and rapid urease test, as no relevant new data
re available. Culture allows performing standard susceptibility
esting to antimicrobial agents; however the technique is complex
nd is performed in very few centres in Italy. Thus, in Italy culture
annot be recommended in clinical practice before ﬁrst-line treat-
ent. When endoscopy is otherwise clinically indicated, culture
nd standard susceptibility testing should be considered, before
econd-line treatment, and when second-line treatment has failed
1]
Molecular tests, which can be performed directly on gastric
amples, allow obtaining data on both clarithromycin and ﬂuoro-
uinolone resistance by polymerase chain reaction (PCR) analysis of
P DNA point mutations, such as 23S rRNA for clarithromycin and
yrA gene for levoﬂoxacin [44,45]. Molecular tests have high
ccuracy, in particular for assessing HP clarithromycin suscepti-
ility, compared to culture with standard susceptibility testing,
ith the advantage of a superior feasibility [46]. However, in a
ecent study carried out in Korea the sensitivity of this methodr Disease 47 (2015) 903–912
in detecting antimicrobial resistance was  not satisfactory [47].
Local validation studies assessing the accuracy of commercially
available kits on representative sample of patients in Italy are
certainly needed. Molecular methods have the potential limita-
tion of a decreasing sensitivity in detecting resistance rates in
relation to progressive occurrence of novel point mutations [48].
Molecular tests are a promising tool that may  ﬁnd a larger appli-
cation in clinical practice in the future, if culture with standard
susceptibility testing is not available, even before a ﬁrst-line
treatment [49].
Statements:
Culture with antimicrobial susceptibility testing is limited to
few centres. Therefore, it cannot be considered a routine inves-
tigation.
Evidence level: 1b; Grade of recommendation: A
Molecular tests may  be a valid alternative for detecting
clarithromycin and/or ﬂuoroquinolone resistance on gastric
biopsies.
Evidence level: 1b; Grade of recommendation: B
3.3. Treatment
3.3.1. Basic principles
Proton pump inhibitor dose. High dose PPI (twice a day) is more
effective than standard dose for eradicating HP infection. Often PPI
is under-dosed in therapeutic regimens in primary care. “In vitro”
studies show that antibiotic minimum inhibitory concentration is
affected by intragastric pH [50]. An Italian study [51] and a meta-
analysis [52] clearly state that PPIs need to be administered at a
high dose to obtain the optimal outcome.
Retreatment after a previously failed regimen. Retreatment is
required when treatment failure is demonstrated, and cannot be
performed on the sole basis of symptoms persistence. The failure
of a clarithromycin-containing ﬁrst-line therapy is very likely to be
associated with a primary or acquired clarithromycin resistance.
Therefore, in these cases the use of clarithromycin in a second-line
treatment is strongly discouraged for the high probability of failure
[53].
Use of other antibiotics. Cephalosporins, quinolones other than
levoﬂoxacin (i.e. moxiﬂoxacin), some tetracyclines (doxycyclin)
should not be used in HP treatment for their poor effectiveness
(<80%). [54,55]. Their use is, therefore, discouraged.
3.3.2. First-line treatment
Over the last decade the efﬁcacy of standard 7-day PPI-based
triple therapy (PPI + clarithromycin + amoxicillin or metronida-
zole/) has fallen to unacceptably low rates [1] due to the increased
prevalence of clarithromycin resistance [56]. A recent Cochrane
systematic review and meta-analysis of RCTs including 45 stud-
ies showed that a 14-day clarithromycin-containing triple therapy
was more effective than 10- and 7-day regimens yielding an
overall eradication rate >80% [57]. This ﬁnding conﬁrmed the
results of a previous meta-analysis showing that 14-day triple
therapy was signiﬁcantly more effective than 7-day triple therapy
[58].
The standard 10-day sequential therapy has shown high efﬁcacy
in ﬁrst-line HP treatment yielding eradication rates of about 90%
[59]. Sequential therapy has been the most studied regimen in Italy
and its high efﬁcacy was also conﬁrmed in clinical practice [60]. This
regimen seems to be able to overcome the issue of clarithromycin
resistance [59]. A recent systematic review and meta-analysis of 46
RCTs showed that sequential therapy was superior to 7- and 10-day
triple therapy, but similar to 14-day triple therapy [61]. The efﬁ-
cacy of sequential therapy was also similar to 10-day concomitant
d Live
(
t
r
w
m
a
h
f
s
a
r
l
o
a
l
e
t
t
t
a
i
s
3
d
n
s
a
e
e
c
[
t
a
o
b
A
I
c
t
m
a
t
t
a
r
w
t
S
O
m
E
T
m
ER.M. Zagari et al. / Digestive an
non-bismuth quadruple) therapy [61]. In Italy, a study conﬁrmed
he good performance of concomitant therapy with an eradication
ate of 90% [62]. This study also reported a high eradication rate
ith so-called “hybrid” therapy, which includes a 14-day treat-
ent with PPI and amoxicillin and the addition of clarithromycin
nd metronidazole during the second week. However, data on
ybrid therapies need to be conﬁrmed in larger studies. No dif-
erence was found in terms of adverse events between 14-day
tandard triple, 10-day sequential and 10-day concomitant ther-
pies [61].
According to the European guidelines, the choice of ﬁrst-line
egimen in a given country should be driven by the local preva-
ence of HP strains with clarithromycin resistance; a threshold
f 15–20% has been recommended to deﬁne countries with low
nd high clarithromycin resistance rates [1]. The European guide-
ines recommend standard clarithromycin triple therapy with an
xtended duration to 10–14 days in low clarithromycin resis-
ance areas; in alternative to a bismuth-containing quadruple
herapy (PPI + bismuth + tetracycline + metronidazole), a sequen-
ial or a concomitant therapy in high clarithromycin resistance
reas [1]. Unfortunately, Italy lacks a national monitoring of clar-
thromycin resistance rates. Studies carried out in selected patients
howed clarithromycin resistance rates ranging between 10% and
5% across the country [56,63,64], with resistance rates varying in
ifferent Italian regions [63]. Therefore, a ﬁrst-line regimen can-
ot be identiﬁed based on clarithromycin resistance rates. The
tandard 14-day clarithromycin-containing triple therapy as well
s the 10-day sequential or concomitant therapies can all be consid-
red effective ﬁrst-line regimens in Italy (Table 2). However, recent
vidence would discourage the use of a 10-day clarithromycin-
ontaining triple therapy in view of sub-optimal eradication rates
57,61].
Sequential therapy is less expensive than both 14-day
riple and concomitant therapies. However, studies speciﬁcally
ddressing cost-effectiveness of sequential therapy compared with
ther eradication regimens are lacking.
When available in Italy, an alternative ﬁrst-line treatment may
e the ‘3-drug pill’ (i.e., bismuth, metronidazole and tetracycline).
 large multicentre European RCT with this regimen (including
taly) reported eradication rates >90%, even in patients harbouring
larithromycin-resistant strains [65].
In case of penicillin allergy, both sequential and concomitant
herapies are not feasible, and a 14-day PPI-clarithromycin-
etronidazole triple regimen should be used.
The use of levoﬂoxacin in ﬁrst-line therapy should be discour-
ged, due to its important role in second-line regimens. Indeed,
he strategy using a clarithromycin-containing therapy as initial
reatment and a levoﬂoxacin-containing therapy as rescue regimen
chieved higher eradication rates than the opposite sequence [66].
When choosing an empirical ﬁrst-line regimen among those
ecommended, Italian physicians should take into account what
orks best in their clinical practice and in their region, as well as
he patient’s preference [67].
tatements:
ne of the following regimens should be used as ﬁrst-line treat-
ent in Italy:
- standard 14-day PPI-based clarithromycin-containing triple
therapy
- 10-day sequential therapy
- 10-day concomitant therapy (non-bismuth quadruple).vidence level: 1a; Grade of recommendation: A
he “3-drug pill” (bismuth, metronidazole and tetracycline)
ay  represent a valid alternative, when available.
vidence level: 1b; Grade of recommendation: Ar Disease 47 (2015) 903–912 907
3.3.3. Second-line treatment
Current European guidelines recommend as second-line treat-
ment either bismuth-containing quadruple therapy or 10-day
levoﬂoxacin-containing triple therapy [1]. A recent meta-analysis
of RCTs, including those performed in Italy, supports the use of a
10-day levoﬂoxacin-containing triple therapy as a simple second-
line therapy for HP eradication (Table 2) [68]. This meta-analysis
showed that triple therapy with PPI + levoﬂoxacin + amoxicillin
was not inferior in terms of efﬁcacy to the more complex
bismuth-containing quadruple therapy, providing cure rates of
88%. On the other hand, the incidence of side effects was  lower
with levoﬂoxacin-containing triple therapy than with bismuth-
containing quadruple therapy. When considering levoﬂoxacin
dosage, a sub-group analysis showed no signiﬁcant difference in
effectiveness between 500 mg  (either once a day or 250 mg  twice a
day) and 1000 mg  (500 mg  twice a day) regimens, so that the low-
dose regimen should be preferred [68]. Two  different levoﬂoxacin-
containing regimens, a 10-day sequential and a 5-day concomitant,
have both shown high eradication rates in a region of Southern
Italy [69,70]. Whether these regimens may  represent an alternative
to levoﬂoxacin-containing triple therapy needs to be con-
ﬁrmed. However, an increased prevalence of primary levoﬂoxacin
resistance has been recently reported in Italy and this may
affect the efﬁcacy of levoﬂoxacin-based regimens [64]. Approaches
to improve HP eradication may  include extending therapy
duration.
Bismuth salts are no longer available in most Italian areas.
However, when available, bismuth-containing quadruple ther-
apy represents a valid alternative second-line treatment for HP
infection (Table 2) [1]. With respect to duration, 14-day treatment
seems to provide higher eradication rates than 7-day treatment
(Intention to treat analysis: 85.6% vs 81.6%; Per protocol analysis:
96.2% vs 89.6%, respectively) [71]. A potential role for quadru-
ple therapy with the novel ‘3-drug pill” is foreseeable in this
setting [65].
Statement: After failure of ﬁrst-line therapy, 10-day
levoﬂoxacin-amoxicillin triple therapy should be used as
second-line treatment. Bismuth-containing quadruple therapy
is an alternative, if available.
Evidence level: 1a; Grade of recommendation: A
3.3.4. Third-line treatment
After two treatment failures, the European guidelines recom-
mend HP culture and susceptibility testing [1] to allow a better
choice of rescue antibacterial treatment based on the antimicrobial
resistance pattern of the speciﬁc HP strain. Therefore, after two
HP treatment failures, patients should be referred to a specialist
setting. However, in clinical practice a culture-based approach is
often unfeasible in Italy. Although data on empirical third-line
therapy are very scanty, there is evidence in clinical practice
of a cumulative 90–95% HP eradication rate using levoﬂoxacin-
amoxicillin triple therapy and bismuth-containing quadruple
therapy as second- and third-line regimens [72]. Therefore, after
a failure of second-line treatment with 10-day levoﬂoxacin triple
therapy, bismuth-containing quadruple therapy should be used
as third-line treatment whenever bismuth salts are available.
A rifabutin-based regimen should be used in the treatment of
refractory HP infection, namely in patients in whom all previous
treatments failed. Rifabutin is an antimycobacterial drug generally
used to cure or prevent Mycobacterium avium- and Mycobacterium
intracellular-related diseases. For this reason, the resistance of HP
to rifabutin is very low in the general health population [1]. In
most studies rifabutin was  prescribed at a dose of 300 mg daily
(either 150 mg  twice a day or 300 mg  once a day) for 10 days,
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Table  2
Treatment regimens recommended for ﬁrst- and second-line therapy of Helicobater pylori infection in Italy.
Therapeutic regimen Duration Drugs and doses
First-line therapy
Clarithromycin-containing triple therapy 14 days - PPI, standard dose twice a day
- Clarithromycin, 500 mg twice a day
-  Amoxicillin, 1000 mg  twice a day, or
- Metronidazole or tinidazole, 500 mg  twice a day
Sequential therapy 10 days:
First 5 days
Followed by 5 days
- PPI, standard dose twice a day
- Amoxicillin, 1000 mg  twice a day,
- PPI, standard dose twice a day
- Clarithromycin, 500 mg twice a day
-  Metronidazole or tinidazole, 500 mg  twice a day
Concomitant therapy (non-bismuth quadruple) 10 days - PPI, standard dose twice a day
- Clarithromycin, 500 mg twice a day
-  Amoxicillin, 1000 mg  twice a day
- Metronidazole or tinidazole, 500 mg  twice a day
Second-line therapy
Levoﬂoxacin-containing triple therapy 10 days - PPI, standard dose twice a day
- Levoﬂoxacin, 500 mg once a day or 250 mg twice a day
-  Amoxicillin, 1000 mg  twice a day
Bismuth-containing quadruple therapy (when
bismuth is available)
7–14 days - PPI, standard dose twice a day
- Bismuth salts, four times a day
- Tetracycline, 500 mg three times a day
-  Metronidazole, 500 mg three times a day
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roviding eradication rates of about 70% [73]. An Italian study
ecently conﬁrmed the efﬁcacy of rifabutin in patients with strains
esistant to single or multiple antibiotics [74]. However, both the
ost and side effects of rifabutin should be taken into account
efore starting this regimen [73].
tatement: After failure of a second-line regimen, treat-
ent should be guided by antimicrobial susceptibility testing.
onetheless, referral to specialist setting is strongly advised.
vidence level: 3a; Grade of recommendation: A
.3.5. Adjuvant treatment with probiotics
In recent years, the use of probiotics as adjuvant therapies in
P eradication has been extensively studied. Certain probiotics,
uch as Lactobacilli, Biﬁdobacteri and Saccaromyces boulardii, exert
n vitro anti-HP activity and are helpful in reducing adverse effects
ssociated with antibiotics [75,76].
Three recent meta-analyses have better clariﬁed the role of
robiotics in the treatment of HP infection [77–79]. Whang et al.
erformed a meta-analysis including 10 clinical trials comparing
actobacillus- and Biﬁdobacterium-containing probiotics with no
ntervention during standard triple therapy [77]. They showed a
educed incidence of side effects in the probiotics supplementation
roup compared to the group without probiotics (OR: 0.30, 95% CI:
.11–0.79). Another meta-analysis, including 9 RCTs, evaluated the
se of Lactobacilli as adjuvant to triple therapy. This meta-analysis
howed a reduction of overall adverse effects, although this was
ot statistically signiﬁcant [78]. Five RCTs comparing Saccaromyces
oulardii administered concurrently to triple therapy with placebo
r no intervention were selected by the third meta-analysis [79].
he use of probiotics signiﬁcantly reduced adverse events, espe-
ially diarrhoea. All three meta-analyses also reported an increased
radication rate with probiotics supplementation [77–79].However, standard 7-day clarithromycin-containing triple
herapy was used in the majority of the trials included in these
eta-analyses [77–79]. Recent studies conﬁrmed the beneﬁcial
ffect of probiotics in reducing side effects even when added to14-day triple therapy [80] or to sequential therapy [81], but no
beneﬁt on eradication rate was  shown with these regimens. More
studies are needed to better deﬁne the effect of probiotics on
eradication rate when added to regimens currently used in clinical
practice.
Statement: Some probiotics reduce adverse effects during HP
eradication therapy.
Evidence level: 3a; Grade of recommendation: B
3.4. HP and prevention of gastric cancer
Two recent meta-analyses conﬁrmed HP as a strong risk factor
for gastric cancer [82,83], reporting that HP eradication signiﬁ-
cantly reduced the risk of developing gastric cancer.
There is strong evidence that HP exerts a direct mutagenic
effects in animal models and cell lines [84,85]. The bacterium has
developed strategies to damage the DNA of gastric epithelium cells,
thus contributing to the development of gastric neoplasia. The
genotoxic properties of HP are the result of inﬂammatory cells
chronically inﬁltrating the gastric mucosa generating reactive oxy-
gen and nitrogen species that may  damage cell DNA, involving the
activation of bacterial virulent factors, such as urease, CagA and
VacA [84,85]. In this respect, the gastric tumourigenic pathway
is similar to that of other tumours caused by chronic inﬂamma-
tion. Although the risk of gastric cancer is inﬂuenced by bacterial
virulence factors, their identiﬁcation cannot currently be recom-
mended in clinical practice [1].
Extensive epidemiological research, especially from Asia, has
shown that the interplay between HP infection, host genetic
conditions and environmental factors result in a wide variability
of gastric cancer incidence among different regions [67,86,87]. In
the Hehuang valley in China, the prevalence of HP-infected gastric
cancers is astonishingly low and environmental factors could be
associated with this malignancy [88]. To the contrary, in a study
from Bhutan, 86% of the gastric cancer population was  HP-infected
while environmental factors seemed to play a minor role, thus
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eading to the conclusion that the high gastric cancer incidence
n this country was mainly due to HP infection [89]. Therefore, a
ultifactorial view of the diversity in gastric cancer aetiology (HP,
ost genetic factors and environment) should be accepted, further
nalyzed and used for an adequate prevention of this malignancy
90].
tatement: HP infection is the most consistent risk factor for
astric cancer.
vidence level: 1a; Grade of recommendation: A
Gastric mucosal inﬂammation may  result in mucosal atro-
hy, deﬁned as “loss of appropriate glands” [91]. Histologically
roven atrophic gastritis with or without intestinal metaplasia is
n unequivocal gastric precancerous condition. Both the atrophy
core and the atrophy-topography are strictly related to the risk
f ‘intestinal type’ gastric cancer and this is the biological ratio-
ale for gastritis staging [92]. The gold standard in atrophy scoring
s the combination of endoscopic and histological ﬁndings. Appro-
riate gastric biopsy sampling with two biopsy samples from the
ntrum, one biopsy sample from the “incisura angularis” and two
iopsy samples from the corpus mucosa is mandatory for atrophy
ssessment [92].
One of the functional consequences of severe corpus atrophic
astritis is hypochlorhydria. A decrease in acid secretion allows
he overgrowth of non-HP bacterial ﬂora, which produces metabo-
ites with carcinogenic potential [93]. HP eradication abolishes
he inﬂammatory response and slows down or may  arrest the
rogression of atrophy; in some cases, it may  even reverse atrophy
1].
tatement: The risk of gastric cancer is associated with long-
tanding gastritis and severity of gastric atrophy/intestinal
etaplasia.
vidence level: 1c; Grade of recommendation: A
HP eradication for gastric cancer prevention may be cost-
ffective in certain communities at high risk for gastric cancer [1].
he meta-analysis by Ford et al. shows that the number of patients
eeded to be treated for preventing a single case of gastric cancer is
5 in China compared to 245 in USA [83]. A strong effort is required
o identify communities at high risk for gastric cancer, where a test-
nd-treat “policy” would be indicated; for instance in areas with
astric cancer incidence rates above 10/100.000 subjects per year,
uch as Asia and Central America, or Marche and Umbria in Italy,
here incidence is over 15/100.000 subjects per year [86]. Since
P eradication offers clinical and ﬁnancial beneﬁts in addition to
astric cancer prevention, the analysis should also consider local
radication costs and antibiotic resistance prevalence in a classic
ost/effectiveness analysis.
In this context, attention should always be given to other
ausative (co)factors of gastric cancer (i.e., smoking and dietary
actors) [94].
tatement: HP eradication is the most promising strategy to
educe the incidence of gastric cancer, particularly in high-
ncidence countries. However, the preventive value of this
trategy has to be fully evaluated in Western countries.
vidence level: 1a; Grade of recommendation: AAmong the possible serological tests, pepsinogens I and II (PgI
nd PgII), Gastrin-17 and HP serology are considered potential
arkers for gastric mucosal atrophy. PgI, PgII and the PgI/PgIIr Disease 47 (2015) 903–912 909
ratio are the most widely applied gastric atrophy markers with
excellent negative predictive value [95]. A PgI/PgII ratio lower than
3 strongly suggests clinically relevant gastric mucosal atrophy
and prompts gastroscopy with multiple biopsies [95,96]. A recent
meta-analysis showed that a panel test based on serum assay of
PgI and PgII, Gastrin-17 and anti-HP IgG has a high sensitivity (80%)
and speciﬁcity (90%) for the non-invasive diagnosis of atrophic
gastritis [97].
Statement: Validated serological tests are available to identify
extensive gastric mucosal atrophy. This enables to avoid inva-
sive diagnostic procedures in patients without other indications
and to select candidates for endoscopy for adequate gastric
biopsy sampling.
Evidence level: 1a; Grade of recommendation: B
HP should be searched and eradicated in individuals with
increased risk for gastric cancer, including: patients with a history
of gastric cancer previously treated by endoscopic or subtotal
gastric resection [98]; ﬁrst-degree relatives of gastric cancer
patients [99]; patients treated with proton pump inhibitors for
more than one year [100]; subjects exposed to environmental risk
factors (i.e. heavy smokers, individuals with high exposure to dust,
coal, quartz, cement) [101,102].
Statement: HP testing and eradication should be considered in
the following groups to prevent gastric cancer:
- Patients with previous gastric neoplasia after endoscopic or
surgical therapy
- First-degree relatives of patients with gastric cancer
- Patients with chronic gastric acid inhibition for more than
one year
- Patients with strong environmental risk factors for gastric
cancer (heavy smoking, high exposure to dust, coal, quartz,
cement)
Evidence level: 1a-4; Grade of recommendation: A
Gastric atrophy is the “ﬁeld” in which intestinal-type gastric
cancer develops. The European guidelines recommend endoscopic
surveillance with multiple gastric biopsies every three years, even if
HP infection was eradicated in patients with extensive (both in the
antrum and corpus) atrophic gastritis and/or intestinal metaplasia
[92].
However, both mucosal atrophy extent (i.e. topography) and
severity (i.e. histology score) parallel gastric cancer risk [92]. Inter-
nationally validated trials consistently recognize the reliability of
gastritis staging based on topography and severity of the atrophic
changes in predicting the risk of gastric cancer. Two staging
systems have been proposed: (i) the operative link for gastritis
assessment (OLGA) staging, based on the global assessment of
atrophy; (ii) the operative link for gastric intestinal metaplasia
(OLGIM) staging, scoring the mucosal topography of intestinal
metaplasia only. OLGA staging is more sensitive than OLGIM
in predicting gastric cancer risk [102]. OLGA staging stratiﬁes
atrophic gastritis in 5 stages (0-IV) and identiﬁes Stages III and
IV (patients with severe antrum or corpus atrophy or moderate
atrophy in both antrum and corpus) as those with high-risk for
gastric cancer [103,104] eligible for surveillance (Fig. 1). Atrophic
gastritis stages signiﬁcantly correlate with serological PgI/PgII ratio
[103]. The risk of gastric cancer is signiﬁcantly higher in patients
with dysplasia (also deﬁned intra-epithelial neoplasia [IEN]),
whose management should be based on the severity of dysplasia.
Surveillance should be performed every year with extensive biopsy
sampling of the gastric mucosa in case of low-grade dysplasia/IEN,
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is/intestinal metaplasia or gastric dysplasia.
hile high-grade dysplasia/IEN should be best removed with
ndoscopic submucosal dissection (ESD). Histologically complete
esection at ESD does not require further surgery.
tatement: Gastric precancerous conditions (atrophic gastritis
nd/or intestinal metaplasia) require endoscopic surveillance.
vidence level: 2a; Grade of recommendation: A
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